楷莱在卵巢癌中的治疗进展.pptVIP

Overall clinical benefit assessed by endpoints of: Response Rate Time to Progression (TTP) Overall Survival The overall response rate (CR+PR) for DOXIL-treated patients was 19.7% and for topotecan-treated patients was 17.6% The median duration of response was 6.9 moth and 5.9 months for DOXIL and topotecan-treated patients respectively Time to progression (TTP) DOXIL median TTP was 4.1 months?; range, 1.3 to 106.9 months Overall survival (OS) DOXIL median OS was 14.4 months?; range, 1.7 to 258.3 weeks. In the DOXIL-treated arm 7.9% and 4.2% of patients had Grade 3 and $ neutropenia. The the topotecan arm the values were 14.0% and 62.1% respectively. Grades 3 and 4 anemia were reported in 5.4% and 0.4% of patients. In contrast in the topotecan-treated patients these were 25.1% and 4.3% Grades 3 thrombocytopenia occurred in 1.3% of patients who received DOXIL. No DOXIL-treated patients had grade 4 thrombocytopenia. In the topotecan-treated patents 17% of patients developed Grade 3 thrombocytopenia and 17% also developed Grade 4 thrombocytopenia Grades 3 and 4b non-hematologic events were similar between the two groups with the following exceptions: There was more stomatitis and HFS in the DOXIL-treated patients and more Grade 4 fever and nausea in the topotecan-treated group In platinum-sensitive patients, a significant difference in favor of DOXIL was observed with regard to time to progression, with medians of 28.9 weeks (DOXIL) and 23.3 weeks (topotecan) observed (P = .037). Gordon AN, Fleagle JT, Guthrie D, et al. J Clin Oncol. 2001;19:3312-3322. Treatment with DOXIL required significantly fewer dose modifications than did treatment with topotecan. The primary reasons for dose modification were HFS in the DOXIL group (25% of doses) and hematologic toxicity in the topotecan group (43% of doses). DOXIL-treated patients required significantly fewer dose delays and dose reductions than did patients treated with topotecan. The frequency of study disco